12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·4 hours agoALT-2.53%OTLK-18.33%
Nexalin Appeals Nasdaq Delisting Following Compliance ShortfallsTip Ranks·18 hours agoNXL-22.51%.IXIC-3.00%
Nexalin appeals Nasdaq delisting notice after failing $1 minimum bid requirementPUBT·18 hours agoNXL-22.51%
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of LifeUnusual Whales·Jun 16 at 08:17 AMNXL-22.51%
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.Unusual Whales·Jun 10 at 08:17 AMNXL-22.51%
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Lifebenzinga_article·Jun 10 at 08:01 AMNXL-22.51%
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia | NXL Stock NewsStockTitan·Jun 4 at 01:01 AMNXL-22.51%
Nexalin Technology shares are trading higher after the company announced it secured neurostimulation legislative provision in the U.S. House Fiscal Year 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill.benzinga_article·May 21 at 08:23 AMNXL-22.51%IBB+0.44%
Nexalin Acquires AI Health Platform Ahead Of HALO Clarity Pivotal Trialnasdaq·May 19 at 08:35 AMNXL-22.51%IHI+2.56%
Nexalin Technology, Inc. 1Q 2026: Revenue $14.95K, EPS ($0.11) — 10-Q SummaryTradingView·May 8 at 01:41 PMNXL-22.51%LABD+4.91%
Nexalin Tech | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 14.95 KEarnings Watch·May 8 at 01:36 PMNXL-22.51%
